ES3042447T3 - Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer - Google Patents

Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer

Info

Publication number
ES3042447T3
ES3042447T3 ES22744048T ES22744048T ES3042447T3 ES 3042447 T3 ES3042447 T3 ES 3042447T3 ES 22744048 T ES22744048 T ES 22744048T ES 22744048 T ES22744048 T ES 22744048T ES 3042447 T3 ES3042447 T3 ES 3042447T3
Authority
ES
Spain
Prior art keywords
compound
egfr
salt
cancer
disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22744048T
Other languages
English (en)
Spanish (es)
Inventor
Erika Butler
Caitlin Kinkema
Christopher Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Application granted granted Critical
Publication of ES3042447T3 publication Critical patent/ES3042447T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES22744048T 2021-06-23 2022-06-22 Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer Active ES3042447T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163214089P 2021-06-23 2021-06-23
PCT/US2022/034550 WO2022271846A1 (en) 2021-06-23 2022-06-22 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (1)

Publication Number Publication Date
ES3042447T3 true ES3042447T3 (en) 2025-11-20

Family

ID=82608408

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22744048T Active ES3042447T3 (en) 2021-06-23 2022-06-22 Salt and crystal form of an azetidinyl substituted isoquinline acting as epidermal growth factor receptor inhibitor for the treatment of cancer

Country Status (9)

Country Link
US (1) US20240293404A1 (enExample)
EP (1) EP4359400B1 (enExample)
JP (1) JP2024523506A (enExample)
CN (1) CN117836287A (enExample)
CA (1) CA3223859A1 (enExample)
ES (1) ES3042447T3 (enExample)
IL (1) IL309469A (enExample)
TW (1) TW202317543A (enExample)
WO (1) WO2022271846A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
IL309447A (en) * 2021-06-23 2024-02-01 Blueprint Medicines Corp Pharmaceutical preparations of epidermal growth factor receptor inhibitor
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Ｃｓ醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
JP7752617B2 (ja) * 2019-12-23 2025-10-10 ブループリント メディシンズ コーポレイション Ｅｇｆｒの変異型の阻害剤
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
IL309447A (en) * 2021-06-23 2024-02-01 Blueprint Medicines Corp Pharmaceutical preparations of epidermal growth factor receptor inhibitor
CN117881670A (zh) * 2021-06-23 2024-04-12 缆图药品公司 制备egfr抑制剂的方法

Also Published As

Publication number Publication date
CN117836287A (zh) 2024-04-05
EP4359400B1 (en) 2025-07-02
US20240293404A1 (en) 2024-09-05
IL309469A (en) 2024-02-01
EP4359400A1 (en) 2024-05-01
TW202317543A (zh) 2023-05-01
WO2022271846A1 (en) 2022-12-29
CA3223859A1 (en) 2022-12-29
JP2024523506A (ja) 2024-06-28

Similar Documents

Publication Publication Date Title
ES2928169T3 (es) Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos
WO2021218110A1 (zh) 一类苯并噻唑基联芳基类化合物、制备方法和用途
ES3054794T3 (en) 4-aminoquinazoline compound
ES2966512T3 (es) Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración
WO2020253860A1 (zh) 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
ES2956943T3 (es) Forma cristalina de AZD9291 deuterado, procedimiento de preparación para la misma y uso de la misma
BR112020005463A2 (pt) formas cristalinas
KR101668931B1 (ko) 항종양제의 효과 증강제
BR112021005513A2 (pt) derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
US20240293404A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
AU2019218186B2 (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
WO2020114388A1 (zh) 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
ES2902521T3 (es) Derivados de aminopiridina y su uso como inhibidores selectivos de ALK-2
WO2022271630A1 (en) Egfr inhibitors
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
ES2981015T3 (es) Forma cristalina de compuesto que suprime la actividad de la proteína quinasa y aplicación de la misma
BR112021005750A2 (pt) inibidor de fgfr4 e uso do mesmo
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
WO2024188086A1 (zh) 芳香酰胺类衍生物及其制备方法和用途
US20240308981A1 (en) Heterocyclic egfr inhibitors for use in the treatment of cancer
WO2021036814A1 (zh) 吡唑衍生物及其用途
HK40104230A (zh) 表皮生长因子受体抑制剂的盐和晶体形式
US20200399284A1 (en) Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
WO2026026870A1 (zh) 环状内酯化合物及其医药用途
WO2023245015A2 (en) Phenyl amide compounds and methods of use